A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy
Interventional
Primary Purpose: Treatment
United States: Food and Drug Administration
OSI-904-203
NCT00116909
August 2004
August 2005
Name | Location |
---|---|
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Sarah Cannon Cancer Center | Nashville, Tennessee 37203 |
Stony Brook University Hospital | Stony Brook, New York 11794-8174 |
The Vanderbilt Cancer Center | Nashville, Tennessee 37232 |